Loading…

Oral delivery of a renin inhibitor compound using emulsion formulations

The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical research 1992-07, Vol.9 (7), p.888-893
Main Authors: Kararli, T T, Needham, T E, Griffin, M, Schoenhard, G, Ferro, L J, Alcorn, L
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c252t-865f1777e99dccdb2d55e2ad83454ecc385fe4468d1188c3398ebf49c83e1df33
cites
container_end_page 893
container_issue 7
container_start_page 888
container_title Pharmaceutical research
container_volume 9
creator Kararli, T T
Needham, T E
Griffin, M
Schoenhard, G
Ferro, L J
Alcorn, L
description The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based on their proposed effects on membrane structure, membrane fluidity, and solute transport. The percent absolute bioavailability (%AB) of I was increased from 0.3% (water suspension) to 5.1% when long-chain unsaturated fatty acid (oleic acid, linoleic acid, etc.)- and mono- and diglyceride (monolein, dilaurin, etc.)-containing emulsion formulations were used. Considering very high first-pass liver extraction of the compound (80%), it is suggested that emulsion formulations increased the intestinal transport of the compound significantly. The solubility of I in aqueous media with and without bile salt (20 mM) was found to be low (approximately 1 micrograms/ml). Incubation in 0.01 N HCl did not affect the particle size of the emulsion. The titration of oleic acid/monoolein emulsion in a pH 6.5 medium with a mixed bile salt system indicated reduction in the particle size of the emulsion. Drug precipitation was observed above 30 mM bile salt concentrations. No drug crystals could be detected in the intestinal contents of the rats when emulsion formulations were ingested. These results suggest that in the intestine of the animals, the particle size of the emulsions is reduced in the presence of bile fluid while the drug resides primarily in the oil phase. The mechanism of enhanced transport of I from the emulsion formulations is discussed along with the possibility of cotransport for the drug and oil. Emulsion formulations can be a potential delivery form for low-bioavailable lipid-soluble drugs.
doi_str_mv 10.1023/A:1015896731545
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73333925</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73333925</sourcerecordid><originalsourceid>FETCH-LOGICAL-c252t-865f1777e99dccdb2d55e2ad83454ecc385fe4468d1188c3398ebf49c83e1df33</originalsourceid><addsrcrecordid>eNotj79LAzEcxTMotVZnJyGT22l-NolbKVqFQhedj1zyjUbukprcCf73Hti3vM_w4cFD6IaSe0oYf9g8UkKlNmvFqRTyDC2JYqLRStALdFnrFyFEUyMWaEEF14SwJdodiu2xhz7-QPnFOWCLC6SYcEyfsYtjLtjl4Zin5PFUY_rAMEx9jTnhkMuMdpy5XqHzYPsK16deoffnp7ftS7M_7F63m33jmGRjo9cyUKUUGOOd8x3zUgKzXnMhBTjHtQwgxFp7SrV2nBsNXRDGaQ7UB85X6O5_91jy9wR1bIdYHfS9TZCn2io-xzA5i7cnceoG8O2xxMGW3_b0nP8BwMxZVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73333925</pqid></control><display><type>article</type><title>Oral delivery of a renin inhibitor compound using emulsion formulations</title><source>SpringerLink Online Journals Archive Complete</source><creator>Kararli, T T ; Needham, T E ; Griffin, M ; Schoenhard, G ; Ferro, L J ; Alcorn, L</creator><creatorcontrib>Kararli, T T ; Needham, T E ; Griffin, M ; Schoenhard, G ; Ferro, L J ; Alcorn, L</creatorcontrib><description>The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based on their proposed effects on membrane structure, membrane fluidity, and solute transport. The percent absolute bioavailability (%AB) of I was increased from 0.3% (water suspension) to 5.1% when long-chain unsaturated fatty acid (oleic acid, linoleic acid, etc.)- and mono- and diglyceride (monolein, dilaurin, etc.)-containing emulsion formulations were used. Considering very high first-pass liver extraction of the compound (80%), it is suggested that emulsion formulations increased the intestinal transport of the compound significantly. The solubility of I in aqueous media with and without bile salt (20 mM) was found to be low (approximately 1 micrograms/ml). Incubation in 0.01 N HCl did not affect the particle size of the emulsion. The titration of oleic acid/monoolein emulsion in a pH 6.5 medium with a mixed bile salt system indicated reduction in the particle size of the emulsion. Drug precipitation was observed above 30 mM bile salt concentrations. No drug crystals could be detected in the intestinal contents of the rats when emulsion formulations were ingested. These results suggest that in the intestine of the animals, the particle size of the emulsions is reduced in the presence of bile fluid while the drug resides primarily in the oil phase. The mechanism of enhanced transport of I from the emulsion formulations is discussed along with the possibility of cotransport for the drug and oil. Emulsion formulations can be a potential delivery form for low-bioavailable lipid-soluble drugs.</description><identifier>ISSN: 0724-8741</identifier><identifier>DOI: 10.1023/A:1015896731545</identifier><identifier>PMID: 1438002</identifier><language>eng</language><publisher>United States</publisher><subject>Absorption - drug effects ; Administration, Oral ; Animals ; Bile Acids and Salts - pharmacology ; Chemistry, Pharmaceutical - methods ; Dipeptides - administration &amp; dosage ; Dipeptides - pharmacokinetics ; Emulsions ; Glycerides - pharmacology ; Intestinal Mucosa - metabolism ; Male ; Morpholines - administration &amp; dosage ; Morpholines - pharmacokinetics ; Mouth - metabolism ; Oleic Acid ; Oleic Acids - pharmacology ; Rats ; Rats, Sprague-Dawley ; Renin - antagonists &amp; inhibitors ; Solubility</subject><ispartof>Pharmaceutical research, 1992-07, Vol.9 (7), p.888-893</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c252t-865f1777e99dccdb2d55e2ad83454ecc385fe4468d1188c3398ebf49c83e1df33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1438002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kararli, T T</creatorcontrib><creatorcontrib>Needham, T E</creatorcontrib><creatorcontrib>Griffin, M</creatorcontrib><creatorcontrib>Schoenhard, G</creatorcontrib><creatorcontrib>Ferro, L J</creatorcontrib><creatorcontrib>Alcorn, L</creatorcontrib><title>Oral delivery of a renin inhibitor compound using emulsion formulations</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><description>The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based on their proposed effects on membrane structure, membrane fluidity, and solute transport. The percent absolute bioavailability (%AB) of I was increased from 0.3% (water suspension) to 5.1% when long-chain unsaturated fatty acid (oleic acid, linoleic acid, etc.)- and mono- and diglyceride (monolein, dilaurin, etc.)-containing emulsion formulations were used. Considering very high first-pass liver extraction of the compound (80%), it is suggested that emulsion formulations increased the intestinal transport of the compound significantly. The solubility of I in aqueous media with and without bile salt (20 mM) was found to be low (approximately 1 micrograms/ml). Incubation in 0.01 N HCl did not affect the particle size of the emulsion. The titration of oleic acid/monoolein emulsion in a pH 6.5 medium with a mixed bile salt system indicated reduction in the particle size of the emulsion. Drug precipitation was observed above 30 mM bile salt concentrations. No drug crystals could be detected in the intestinal contents of the rats when emulsion formulations were ingested. These results suggest that in the intestine of the animals, the particle size of the emulsions is reduced in the presence of bile fluid while the drug resides primarily in the oil phase. The mechanism of enhanced transport of I from the emulsion formulations is discussed along with the possibility of cotransport for the drug and oil. Emulsion formulations can be a potential delivery form for low-bioavailable lipid-soluble drugs.</description><subject>Absorption - drug effects</subject><subject>Administration, Oral</subject><subject>Animals</subject><subject>Bile Acids and Salts - pharmacology</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Dipeptides - administration &amp; dosage</subject><subject>Dipeptides - pharmacokinetics</subject><subject>Emulsions</subject><subject>Glycerides - pharmacology</subject><subject>Intestinal Mucosa - metabolism</subject><subject>Male</subject><subject>Morpholines - administration &amp; dosage</subject><subject>Morpholines - pharmacokinetics</subject><subject>Mouth - metabolism</subject><subject>Oleic Acid</subject><subject>Oleic Acids - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Renin - antagonists &amp; inhibitors</subject><subject>Solubility</subject><issn>0724-8741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNotj79LAzEcxTMotVZnJyGT22l-NolbKVqFQhedj1zyjUbukprcCf73Hti3vM_w4cFD6IaSe0oYf9g8UkKlNmvFqRTyDC2JYqLRStALdFnrFyFEUyMWaEEF14SwJdodiu2xhz7-QPnFOWCLC6SYcEyfsYtjLtjl4Zin5PFUY_rAMEx9jTnhkMuMdpy5XqHzYPsK16deoffnp7ftS7M_7F63m33jmGRjo9cyUKUUGOOd8x3zUgKzXnMhBTjHtQwgxFp7SrV2nBsNXRDGaQ7UB85X6O5_91jy9wR1bIdYHfS9TZCn2io-xzA5i7cnceoG8O2xxMGW3_b0nP8BwMxZVg</recordid><startdate>19920701</startdate><enddate>19920701</enddate><creator>Kararli, T T</creator><creator>Needham, T E</creator><creator>Griffin, M</creator><creator>Schoenhard, G</creator><creator>Ferro, L J</creator><creator>Alcorn, L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19920701</creationdate><title>Oral delivery of a renin inhibitor compound using emulsion formulations</title><author>Kararli, T T ; Needham, T E ; Griffin, M ; Schoenhard, G ; Ferro, L J ; Alcorn, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c252t-865f1777e99dccdb2d55e2ad83454ecc385fe4468d1188c3398ebf49c83e1df33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Absorption - drug effects</topic><topic>Administration, Oral</topic><topic>Animals</topic><topic>Bile Acids and Salts - pharmacology</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Dipeptides - administration &amp; dosage</topic><topic>Dipeptides - pharmacokinetics</topic><topic>Emulsions</topic><topic>Glycerides - pharmacology</topic><topic>Intestinal Mucosa - metabolism</topic><topic>Male</topic><topic>Morpholines - administration &amp; dosage</topic><topic>Morpholines - pharmacokinetics</topic><topic>Mouth - metabolism</topic><topic>Oleic Acid</topic><topic>Oleic Acids - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Renin - antagonists &amp; inhibitors</topic><topic>Solubility</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kararli, T T</creatorcontrib><creatorcontrib>Needham, T E</creatorcontrib><creatorcontrib>Griffin, M</creatorcontrib><creatorcontrib>Schoenhard, G</creatorcontrib><creatorcontrib>Ferro, L J</creatorcontrib><creatorcontrib>Alcorn, L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kararli, T T</au><au>Needham, T E</au><au>Griffin, M</au><au>Schoenhard, G</au><au>Ferro, L J</au><au>Alcorn, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral delivery of a renin inhibitor compound using emulsion formulations</atitle><jtitle>Pharmaceutical research</jtitle><addtitle>Pharm Res</addtitle><date>1992-07-01</date><risdate>1992</risdate><volume>9</volume><issue>7</issue><spage>888</spage><epage>893</epage><pages>888-893</pages><issn>0724-8741</issn><abstract>The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based on their proposed effects on membrane structure, membrane fluidity, and solute transport. The percent absolute bioavailability (%AB) of I was increased from 0.3% (water suspension) to 5.1% when long-chain unsaturated fatty acid (oleic acid, linoleic acid, etc.)- and mono- and diglyceride (monolein, dilaurin, etc.)-containing emulsion formulations were used. Considering very high first-pass liver extraction of the compound (80%), it is suggested that emulsion formulations increased the intestinal transport of the compound significantly. The solubility of I in aqueous media with and without bile salt (20 mM) was found to be low (approximately 1 micrograms/ml). Incubation in 0.01 N HCl did not affect the particle size of the emulsion. The titration of oleic acid/monoolein emulsion in a pH 6.5 medium with a mixed bile salt system indicated reduction in the particle size of the emulsion. Drug precipitation was observed above 30 mM bile salt concentrations. No drug crystals could be detected in the intestinal contents of the rats when emulsion formulations were ingested. These results suggest that in the intestine of the animals, the particle size of the emulsions is reduced in the presence of bile fluid while the drug resides primarily in the oil phase. The mechanism of enhanced transport of I from the emulsion formulations is discussed along with the possibility of cotransport for the drug and oil. Emulsion formulations can be a potential delivery form for low-bioavailable lipid-soluble drugs.</abstract><cop>United States</cop><pmid>1438002</pmid><doi>10.1023/A:1015896731545</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0724-8741
ispartof Pharmaceutical research, 1992-07, Vol.9 (7), p.888-893
issn 0724-8741
language eng
recordid cdi_proquest_miscellaneous_73333925
source SpringerLink Online Journals Archive Complete
subjects Absorption - drug effects
Administration, Oral
Animals
Bile Acids and Salts - pharmacology
Chemistry, Pharmaceutical - methods
Dipeptides - administration & dosage
Dipeptides - pharmacokinetics
Emulsions
Glycerides - pharmacology
Intestinal Mucosa - metabolism
Male
Morpholines - administration & dosage
Morpholines - pharmacokinetics
Mouth - metabolism
Oleic Acid
Oleic Acids - pharmacology
Rats
Rats, Sprague-Dawley
Renin - antagonists & inhibitors
Solubility
title Oral delivery of a renin inhibitor compound using emulsion formulations
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T20%3A28%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20delivery%20of%20a%20renin%20inhibitor%20compound%20using%20emulsion%20formulations&rft.jtitle=Pharmaceutical%20research&rft.au=Kararli,%20T%20T&rft.date=1992-07-01&rft.volume=9&rft.issue=7&rft.spage=888&rft.epage=893&rft.pages=888-893&rft.issn=0724-8741&rft_id=info:doi/10.1023/A:1015896731545&rft_dat=%3Cproquest_pubme%3E73333925%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c252t-865f1777e99dccdb2d55e2ad83454ecc385fe4468d1188c3398ebf49c83e1df33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73333925&rft_id=info:pmid/1438002&rfr_iscdi=true